Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-08

Clinical Trial Update: Study of Pemetrexed for Second-Line Pancreas Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of pemetrexed for second-line pancreatic cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alimta (pemetrexed)
  • Pemetrexed (pemetrexed)

Snippet

Sponsor: Georgetown University | Conditions: Pancreas Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-12-08